-
Why Did Sarepta Therapeutics Plunge 20%?
Thursday, June 2, 2016 - 11:26am | 347Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 20 percent on Thursday after reports surfaced that the U.S. Food and Drug Administration may pressure the company to provide its Duchenne muscular dystrophy patients with at-cost access to its eteplirsen therapy on a "...
-
Relypsa Surges 30% Following Setback From Rival AstraZeneca
Friday, May 27, 2016 - 8:09am | 217Read More...Shares of Relypsa Inc (NASDAQ: RLYP) surged higher by more than 30 percent early Friday morning on no corporate news or rumors. According to the TheStreet'sAdam Feuerstein, Relypisa scored a "big win" on Friday after its chief rival AstraZeneca plc (ADR) (NYSE: AZN) confirmed the...
-
Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval
Thursday, April 28, 2016 - 11:15am | 278Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by around 20 percent Thursday morning after The Street's biotech expert Adam Feuerstein penned an article titled "Why Sarepta Can Ultimately Win FDA Drug Approval." Shares of Sarepta were hard hit after a federal...
-
Chiasma Plunges 60% Following FDA Review, CEO 'Surprised, Disappointed And Respectfully Disagree With The Decision'
Monday, April 18, 2016 - 10:34am | 354Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 60 percent Monday morning after the company provided an update regarding its New Drug Application for Mycapssa capsules. Chiasma is a biopharmaceutical company that focuses on treating patients with rare and serious chronic diseases. Its...
-
Chiasma Plunges 14%; Feuerstein Source Says FDA Will Reject Co.'s Therapy Capsules
Thursday, April 14, 2016 - 10:05am | 258Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 14 percent Thursday morning ahead of the U.S. Food and Drug Administration's decision on Friday to approve or reject the company's therapy. Chiasma is a biopharmaceutical company that focuses on the treatment of orphan diseases. The...
-
Clovis Oncology Falls 8%: Here's What You Need To Know
Friday, April 8, 2016 - 2:11pm | 320Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS) lost more than 8 percent on Friday after the company confirmed that the FDA posted briefing documents ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug Application (NDA) for rociletinib. The...
-
Intercept Pharma Investors Cheering FDA Briefing Doc Release
Tuesday, April 5, 2016 - 10:03am | 337Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) were trading higher by more than 6 percent ahead of Tuesday's market open as investors found the U.S. Food and Drug Administration's latest briefing documents to be encouraging. The FDA has a scheduled advisory committee meeting on Thursday and...
-
Sarepta Therapeutics Gives Up Gains Following Notable Tweet
Tuesday, February 23, 2016 - 3:29pm | 313Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher on heavy volume and hit an intra-day high of $15.74 Tuesday afternoon. Sarepta's gain was short-lived as the stock quickly gave up all gains and was trading lower by more than 2 percent mid-Tuesday afternoon. Investors and...
-
Adam Feurestein Reminds Twitter Followers 'Today Is Merck's HepC elbasvir/grazoprevir PDUFA'
Thursday, January 28, 2016 - 12:48pm | 302Read More...The Street's biotechnology and drug stock expert, Adam Feuerstein, reminded his Twitter followers of an important event with the healthcare space. Reminder: Today is $MRK HepC elbasvir/grazoprevir PDUFA. Co. spox knows first and most important post-approval question is: What price? — Adam...
-
Relypsa Lost Major Ground; Feuerstein Tweets Favus Report Said 'Nothing New'
Friday, January 8, 2016 - 9:17am | 331Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 8 percent early Friday morning. The stock plunged more than 13 percent on Thursday following a bear research report by Elliot Favus of Favus Institutional Research. Adam Feuerstein, a senior columnist with The Street and known...
-
Bluebuird Bio Crashes Nearly 30%: What's Next?
Monday, December 7, 2015 - 11:53am | 1162Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...
-
Should Gilead Buy Vertex?
Tuesday, April 21, 2015 - 11:44am | 351Read More...Adam Feuerstein of TheStreet.com on Tuesday discussed the merits of Gilead Sciences, Inc. (NASDAQ: GILD) acquiring Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Tuesday. Feuerstein highlighted a report from Bernstein analyst Geoff Porges that suggested Gilead’s “long...
-
Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals
Tuesday, April 21, 2015 - 11:01am | 283Read More...Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Gilead Sciences, Inc. (NASDAQ: GILD) shares were trading higher by $3.75 (3.5 percent) at $104.40 in Tuesday's session. The catalyst for the rally is a Adam Feuerstein tweet, where he wrote...
-
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
Saturday, April 18, 2015 - 10:49am | 338Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. TheStreet Senior Columnist Adam Feuerstein responded to an article in the Boston Business Journal which suggested that Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA)...
-
Adam Feuerstein Is A Skeptic Of Stem Cell Therapy
Saturday, April 18, 2015 - 10:46am | 259Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. TheStreet Senior Columnist Adam Feuerstein discussed Cytori Therapeutics Inc (NASDAQ: CYTX) on the show. Overall, Feuerstein was skeptical of stem cell therapy...
